These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 10087729)

  • 21. Advanced prostate cancer: what's new in hormonal manipulation?
    Brewster SF; Gillatt DA
    Br J Hosp Med; 1993 May 19-Jun 1; 49(10):710-1, 714-5. PubMed ID: 7686805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced prostate cancer. Hormonal treatment.
    de la Haba-Rodríguez J
    Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hormonal therapy in metastatic prostatic cancer].
    Ruffion A; Fontaine E; Staerman F
    Prog Urol; 2003 Apr; 13(2):334-41. PubMed ID: 12765081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
    Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compliance with hormonal treatment for prostate cancer.
    Kaisary AV
    Br J Hosp Med; 1996 Mar 20-Apr 2; 55(6):359-66. PubMed ID: 8696636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maximal androgen ablation: a review.
    Miles BJ; Babiarz J
    Henry Ford Hosp Med J; 1992; 40(1-2):114-7. PubMed ID: 1428961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiandrogens in the treatment of prostate cancer.
    Wirth MP; Hakenberg OW; Froehner M
    Eur Urol; 2007 Feb; 51(2):306-13; discussion 314. PubMed ID: 17007995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
    Graff JN; Mori M; Li H; Garzotto M; Penson D; Potosky AL; Beer TM
    J Urol; 2007 Apr; 177(4):1307-12. PubMed ID: 17382720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A critical review of the concept of total androgen ablation in the treatment of prostate cancer.
    Schulze H; Isaacs JT; Coffey DS
    Prog Clin Biol Res; 1987; 243A():1-19. PubMed ID: 3309968
    [No Abstract]   [Full Text] [Related]  

  • 32. [Disseminated carcinoma of the prostate: monotherapy or complete androgenic blockade?].
    González Martín M; Gómez Veiga F; Alvarez Castelo L
    Arch Esp Urol; 1997 Dec; 50(10):1067-76. PubMed ID: 9494195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
    Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
    Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrine therapy for prostate cancer.
    Damber JE
    Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
    Spetz AC; Hammar M; Lindberg B; Spångberg A; Varenhorst E;
    J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population based study of hormonal therapy and survival in men with metastatic prostate cancer.
    Lu-Yao G; Moore DF; Oleynick JU; DiPaola RS; Yao SL
    J Urol; 2007 Feb; 177(2):535-9. PubMed ID: 17222628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.